Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses
Authors' conclusion
Effects of vicadrostat with or without empagliflozin on UACR, eGFR, and SBP were consistent irrespective of T2D and obesity status.
Study context
- Population
- Adults with chronic kidney disease (CKD) (eGFR 30 to < 90 mL/min/1.73 m², UACR 200 to < 5000 mg/g) on maximally tolerated RAS inhibitor, with or without T2D; subgroups by T2D and BMI (≥ 30 vs. < 30 kg/m²)
- Participants
- 586 adults
- Comparison
- Vicadrostat vs placebo, with or without background empagliflozin
- Primary endpoint
- Effect on albuminuria (UACR), assessed by T2D and obesity subgroups
- Follow-up
- 14 weeks
Methodological detailssubgroup analysis, placebo-controlled, subgroup analyses by T2D and obesity status
- Subgroup analysis
- Placebo-controlled
- Subgroup analyses by T2D and obesity status
Primary result
As reported in the abstract
Largest UACR reductions with 10 and 20 mg across both subgroup analyses (adjusted mean reduction)
30%-51%
Adjusted mean UACR reduction in the overall study
37%-46%
Further findings
- Effects of vicadrostat on reductions in eGFR and systolic blood pressure (SBP) consistent across T2D and BMI subgroups
Original publication
Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses. Diabetes Obes Metab. Published 5 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →